Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye.

Publisher: Springer Country of Publication: Germany NLM ID: 8804297 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1435-4373 (Electronic) Linking ISSN: 09349723 NLM ISO Abbreviation: Eur J Clin Microbiol Infect Dis Subsets: MEDLINE

Publication: Berlin : Springer
Original Publication: [Wiesbaden, Federal Republic of Germany] : Vieweg, [c1988-

Drug Combinations* ; Cephalosporins*/pharmacology ; Ceftazidime*/pharmacology ; Azabicyclo Compounds*/pharmacology ; Microbial Sensitivity Tests* ; Pseudomonas aeruginosa*/drug effects ; Pseudomonas aeruginosa*/isolation & purification ; Pseudomonas aeruginosa*/genetics ; Pseudomonas aeruginosa*/enzymology ; Pseudomonas Infections*/microbiology ; Tazobactam*/pharmacology ; Anti-Bacterial Agents*/pharmacology ; Cefiderocol*; Humans ; Middle Aged ; Female ; Male ; Adult ; beta-Lactamases/genetics ; beta-Lactamases/metabolism ; Aged ; Carbapenems/pharmacology ; Bacterial Proteins/genetics ; Young Adult ; Adolescent ; beta-Lactamase Inhibitors/pharmacology ; Child

Purpose: Carbapenem resistant Pseudomonas aeruginosa (CR-PA) is escalating worldwide and leaves clinicians few therapeutic options in recent years, β-lactam/β-lactamase inhibitor combinations (ceftolozane-tazobactam, ceftazidime-avibactam) and a new siderophore cephalosporin (cefiderocol) have been approved for the treatment of P. aeruginosa infection and have shown potent activity against isolates defined as carbapenem resistant. The aim of this study was to determine the phenotypic profile of these agents against CR-PA in the emerging setting of carbapenemases.
Methods: CR-PA clinical isolates were collected from three teaching hospitals in different geographical regions between January 2017-December 2021. All isolates were subjected to phenotypic carbapenemase testing using modified carbapenem inactivation method. MICs were determined by reference broth microdilution and evaluated according to EUCAST standards, while genotypic profiling was determined using PCR methods.
Results: 244 CR-PA sourced most frequently from the respiratory tract (32.2%), blood (20.4%) and urine (17.5%) were evaluated. Of all isolates, 32 (13.1%) were phenotypically and 38 (15.6%) were genotypically defined as carbapenemase-positive. The most common carbapenemase was GES (63.1%), followed by VIM (15.8%). The MIC 50/90 (S%) of ceftazidime/avibactam, ceftolozane/tazobactam and cefiderocol in all CR-PA isolates were 4 and 32 (80%), 1 and > 64 (69%) and 0.25 and 1 mg/L (96%), respectively. Cefiderocol was also the most active agent in carbapenemase-positive isolates (90%).
Conslusion: While ceftolozane/tazobactam and ceftazidime/avibactam remained highly active against CR-PA devoid of carbapenemases, cefiderocol provided potent in vitro activity irrespective of carbapenemase production. When considering the potential clinical utility of newer agents against CR-PA, regional variations in carbapenemase prevalence must be considered.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)

Potron A, Poirel L, Nordmann P (2015) Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int J Antimicrob Agents 45:568–585. (PMID: 10.1016/j.ijantimicag.2015.03.00125857949)
Rafael Canton Y, Doi, Patricia J, Simner (2022) Treatment of carbapenem-resistant Pseudomonas aeruginosa infections: a case for cefiderocol. Expert Rev Anti-infective Therapy 20(8):1077–1094. https://doi.org/10.1080/14787210.2022.2071701. (PMID: 10.1080/14787210.2022.207170135502603)
Çekin ZK, Dabos L, Malkoçoğlu G, Fortineau N, Bayraktar B, Iorga BI, Naas T, Aktaş E (2021) Carbapenemase -producing Pseudomonas aeruginosa isolates from Turkey: first report of P. Aeruginosa high-risk clones with VIM-5– and IMP-7–type carbapenemases in a tertiary hospital. Diagn Microbiol Infect Dis 99:115174. (PMID: 10.1016/j.diagmicrobio.2020.11517432980808)
Oliver A et al (2023) Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group. Clin Microbiol Infect.
Hazirolan G, Özkul C (2023) Evaluation of in Vitro Activity of Ceftolozane/Tazobactam and Ceftazidime/Avibactam against Carbapenem-Resistant Pseudomonas aeruginosa Strains and mechanisms of Carbapenem Resistance: data from Tertiary Care Hospital. Jundishapur J Microbiol 16(3):e134090. https://doi.org/10.5812/jjm-134090. (PMID: 10.5812/jjm-134090)
Malkoçoǧlu G, Aktaş E, Bayraktar B, Otlu B, Bulut ME (2017) VIM-1, VIM-2, and GES-5 carbapenemases among pseudomonas aeruginosa isolates at a Tertiary Hospital in Istanbul, Turkey. Microb Drug Resist 23:328–334. (PMID: 10.1089/mdr.2016.001227326514)
Gill CM, Asempa TE, Tickler IA, Cruz C, Dela, Tenover FC, Nicolau DP (2020) Evaluation of the Xpert Carba-R NxG assay for detection of carbapenemase genes in a global challenge set of pseudomonas aeruginosa isolates. J Clin Microbiol 58:1–7. (PMID: 10.1128/JCM.01098-20)
Tamma PD, Aitken SL, Bonomo RA et al (2022) Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to- treat resistance (DTR-P. aeruginosa). Clin Infect Dis 75:187–212. https://doi.org/10.1093/cid/ciac268. (PMID: 10.1093/cid/ciac268354392919890506)
Wilson GM, Fitzpatrick MA, Walding K, Gonzalez B, Schweizer ML, Suda KJ, Evans CT (2021) Evaluating the clinical effectiveness of new beta-lactam/beta-lactamase inhibitor combination antibiotics: a systematic literature review and meta-analysis. Antimicrobial stewardship and Healthcare Epidemiology. Cambridge University Press. https://doi.org/10.1017/ash.2021.217 .
Lee SY, Gill CM, Nicolau DP, on behalf of the ERACE-PA Global Study Group (2023) Activity of Novel β-Lactam/β-Lactamase inhibitor combinations against serine-carbapenemase producing Carbapenem-Resistant Pseudomonas aeruginosa. J Antimicrob Chemother 78(12):2795–2800. (PMID: 10.1093/jac/dkad2253784000510689909)
Kanj SS, Bassetti M, Kiratisin P, Rodrigues C, Villegas MV, Yu Y, van Duin D (2022) Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents Elsevier B V. https://doi.org/10.1016/j.ijantimicag.2022.106633. (PMID: 10.1016/j.ijantimicag.2022.106633)
Yahav D, Giske CG, Gramatniece A, Abodakpi H, Tam VH, Leibovici L (2021) New β-lactam–β-lactamase inhibitor combinations. Clin Microbiol Rev 34:1–61. (PMID: 10.1128/CMR.00021-21)
Horcajada JP et al (2019) Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev 32(4):10–1128. (PMID: 10.1128/CMR.00031-19)
Buyukyanbolu E (2023) June. Determination of the Presence of Carbapenemase enzymes. Carbapenem-Resistant Pseudomonas aeruginosa isolates by susceptibility test based Algorithm. Poster presentation. ASM Microbe, Houston,TX,USA.
CLSI (2023) Performance standards for antimicrobial susceptibility testing, 33th edition. CLSI Supplement M100. Clinical and Laboratory Standards Institute, Wayne.
https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_14.0_Breakpoint_Tables.pdf.
https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2023-2021-data.
Potron A, Poirel L, Nordmann P (2015) Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int J Antimicrob Agents 45(6):568–585. (PMID: 10.1016/j.ijantimicag.2015.03.00125857949)
Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF (2018) In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012–15. J Antimicrob Chemother 73:2777–2781. https://doi.org/10.1093/jac/dky267. (PMID: 10.1093/jac/dky26730010951)
Mirza HC, Hortaç E, Koçak AA, Demirkaya MH, Yayla B, Güçlü AÜ, Başustaoğlu A (2020) In vitro activity of ceftolozane–tazobactam and ceftazidime–avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: a two-centre study. J Glob Antimicrob Resist 20:334–338. (PMID: 10.1016/j.jgar.2019.09.01631568882)
Stone GG, Newell P, Gasink LB, Broadhurst H, Wardman A, Yates K, Chen Z, Song J, Chow JW (2018) Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam phase III clinical trial programme. J Antimicrob Chemother 73:2519–2523. (PMID: 10.1093/jac/dky20429912399)
Sader HS, Castanheira M, Mendes RE, Flamm RK, Farrell DJ, Jones RN (2015) Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Antimicrob Agents Chemother 59:3656–3659. (PMID: 10.1128/AAC.05024-14258458614432162)
Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN (2014) Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). J Antimicrob Chemother 69:2713–2722. https://doi.org/10.1093/jac/dku184. (PMID: 10.1093/jac/dku18424917579)
Grupper M, Sutherland C, Nicolau DP (2017) Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds. Antimicrob Agents Chemother 61:e00875–e00817. https://doi.org/10.1128/AAC.00875-17. (PMID: 10.1128/AAC.00875-17287397805610483)
Humphries RM, Hindler JA, Wong-Beringer A, Miller SA (2017) Activity of ceftolozane-tazobactam and ceftazidime-avibactam against betalactam-resistant Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother 61:e01858–e01817. https://doi.org/10.1128/AAC.01858-17. (PMID: 10.1128/AAC.01858-17289933385700315)
Lee S, Young CM, Gill (2023) Nicolau. Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 78(12):2795–2800. (PMID: 10.1093/jac/dkad2253784000510689909)
Hernández-García M et al (2022) In vitro activity of cefepime-taniborbactam against carbapenemase-producing enterobacterales and Pseudomonas aeruginosa isolates recovered in Spain. Antimicrob Agents Chemother 66(3):e02161–e02121. (PMID: 10.1128/aac.02161-21350071308923209)
de la Ortiz JM, Nordmann P, Poirel L (2019) ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa. J Antimicrob Chemother. ;74(7):1934–1939. https://doi.org/10.1093/jac/dkz149 . PMID: 31225611.
Gill CM (2023) Nicolau. Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 78(1):252–256. (PMID: 10.1093/jac/dkac385)
Karlowsky JA, Hackel MA, Takemura M, Yamano Y, Echols R, Sahm DF (2022) In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies.
Wise MG, Karlowsky JA, Hackel MA, Takemura M, Yamano Y, Echols R, Sahm DF (2023) Vitro Activity of Cefiderocol against Meropenem-Nonsusceptible Gram-negative Bacilli with defined β-Lactamase carriage: SIDERO-WT Surveillance studies, 2014–2019. Microb Drug Resist 29:360–370. (PMID: 10.1089/mdr.2022.02793725315810387160)
Gill CM, Santini D (2023) and David P. Nicolau. In vitro activity of cefiderocol against a global collection of carbapenem-resistant Pseudomonas aeruginosa with a high level of carbapenemase diversity. J Antimicrob Chemother : dkad396.
Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF (2018) In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gramnegative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother 62:e01968–e01917. https://doi.org/10.1128/AAC.01968-17. (PMID: 10.1128/AAC.01968-17291582705786755)
Hsueh S-C, Lee Y-J, Huang Y-T, Liao C-H, Tsuji M, Hsueh P-R (2018) In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/ avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. J Antimicrob Chemother 74:380–386. https://doi.org/10.1093/jac/dky425. (PMID: 10.1093/jac/dky425)
Mirza H, Cenk, Gizem İnce C (2022) Comparison of in vitro activities of cefiderocol, imipenem/relebactam and other antibiotics against carbapenem-resistant Pseudomonas aeruginosa isolates. Turkish Bull Hygiene Experimental Biology 79(3):433–442. (PMID: 10.5505/TurkHijyen.2022.79095)
Uechi K et al (2017) A modified carbapenem inactivation method, CIMTris, for carbapenemase production in Acinetobacter and Pseudomonas species. J Clin Microbiol 55(12):3405–3410. (PMID: 10.1128/JCM.00893-17289548985703807)
Gill CM, Lasko M, Asempa TE, Nicolau DP (2020) Evaluation of the EDTA-Modified carbapenem inactivation method (eCIM) for detecting Metallo-β-lactamase Producing Pseudomonas aeruginosa. J Clin Microbiol 58(6):e02015–e02019. (PMID: 10.1128/JCM.02015-19322384337269398)

Keywords: Antimicrobial susceptibility; Carbapenem resistance; Cefiderocol

0 (Drug Combinations)
0 (Cephalosporins)
9M416Z9QNR (Ceftazidime)
0 (avibactam, ceftazidime drug combination)
0 (Azabicyclo Compounds)
0 (ceftolozane, tazobactam drug combination)
SE10G96M8W (Tazobactam)
0 (Anti-Bacterial Agents)
SZ34OMG6E8 (Cefiderocol)
EC 3.5.2.6 (carbapenemase)
EC 3.5.2.6 (beta-Lactamases)
0 (Carbapenems)
0 (Bacterial Proteins)
0 (beta-Lactamase Inhibitors)

Date Created: 20240712 Date Completed: 20240827 Latest Revision: 20240827

20240828

10.1007/s10096-024-04896-7

38995343